The GU Oncology Now team is onsite at the 2025 American Society of Clinical Oncology Annual Meeting, providing real-time coverage of the most relevant and practice-changing research updates related to prostate, kidney, bladder, and testicular cancer.
Advertisement
Latest News
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
Updated CREST trial explores sasanlimab plus BCG in BCG-naive, high-risk NMIBC, with new insights by disease stage and tumor.
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
The panel concludes with a discussion on the early use of PARP inhibitors in patients with DNA repair mutations like BRCA1/2.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
The Uromigos Live and Unplugged 2024
The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.
This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
Expert Interviews
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Video Insights
Clinical discussions with experts in the field
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.